Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment

NCT05426135 | Recruiting

• 1 other identifier: Jin_cancer risk
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.

Conditions

Artificial Intelligence; Deep Learning; Lung Cancer; Lung; Node; Stomach Cancer; Colon Cancer; Cancer Risk; Cancer Screening; Cancer, Treatment-Related

Outcome Measures

Primary Outcomes (4)

• The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule)

  The outcome of clinical diagnosis of patients with lung cancer/pulmonary nodular (Benign/Malignant nodule). ① Benign nodule ② Malignant neoplasm/nodule: squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and large cell carcinoma.

  2022-2026

• The outcome of clinical diagnosis of suspected patients with stomach cancer or lesion (Benign/Malignant).

  ① Benign ② Malignant

  2022-2026

• The outcome of clinical diagnosis of suspected patients with colorectal cancer or lesion (Benign/Malignant).

  ① Benign ② Malignant

  2022-2026

• Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).

  The treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer follows The Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) from the World Health Organization (WHO). The evaluation index is as follows. CR (complete response): Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm. PR (partial response): 30% decrease in the sum of the longest diameter of the target lesions compared with baseline. PD (progressive disease):≥20% increase of at least 5 mm in the sum of the longest diameter of the target lesions compared with the smallest sum of the longest diameter recorded OR The appearance of new lesions, including those detected by FDG-PET (fludeoxyglucose positron emission tomography). SD (stable disease): Neither PR nor PD.

  2022-2026

Study Arms (3)

Lung cancer group

Participants with lung cancer/pulmonary nodules

Stomach cancer group

Participants with Stomach cancer/Stomach lesion

Colorectal cancer group

Participants with Colorectal cancer/Colorectal lesion

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision

You may qualify if:

• Participants with the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision
• Participants that have signed informed consent.
• Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.
• Healthy participants with no clinical diagnosis of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision.

You may not qualify if:

• Participants with primary clinical and pathological data missing.
• Participants lost to follow-up.
• Participants with too poor medical image quality to perform segment and mark ROI accurately

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead

Study Sites (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Stomach Neoplasms; Colonic Neoplasms; Neoplasms, Second Primary

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Colorectal Neoplasms; Intestinal Neoplasms; Colonic Diseases; Intestinal Diseases

Central Study Contacts

Yang Jin

CONTACT

15107177084; whuhjy@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 15, 2022
• First Posted: June 21, 2022
• Study Start: June 1, 2022
• Primary Completion: October 1, 2025
• Study Completion (Estimated): October 1, 2026
• Last Updated: June 21, 2022

Record last verified: 2022-06

Locations

CN (1)